| Not Yet Recruiting | Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors NCT06027983 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Recruiting | NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry fo NCT07489378 | National Cancer Institute (NCI) | — |
| Recruiting | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors NCT07021066 | SystImmune Inc. | Phase 1 |
| Recruiting | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors NCT06926283 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors NCT06577532 | Ruijin Hospital | EARLY_Phase 1 |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors NCT06466187 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Unknown | KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors NCT05906524 | Shanghai Kanda Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers NCT06358053 | Corregene Biotechnology Co., Ltd | Phase 1 |
| Terminated | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Soli NCT06438783 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W NCT06022757 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Posit NCT05877599 | AstraZeneca | Phase 1 |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Recruiting | Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tu NCT05631964 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor NCT05332574 | Genor Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) NCT05121948 | HiberCell, Inc. | Phase 1 |
| Active Not Recruiting | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors NCT05393427 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) NCT04834778 | HiberCell, Inc. | Phase 1 |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China NCT04121286 | Allist Pharmaceuticals, Inc. | Phase 1 |
| Completed | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairme NCT04256707 | Karyopharm Therapeutics Inc | Phase 1 / Phase 2 |
| Completed | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors NCT04045496 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions NCT03947385 | IDEAYA Biosciences | Phase 1 / Phase 2 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Terminated | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors NCT02709889 | AbbVie | Phase 1 / Phase 2 |
| Completed | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, NCT02819843 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers NCT02711345 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small NCT02573259 | Pfizer | Phase 1 |
| Terminated | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations NCT02607813 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Phase I/II Study of PDR001 in Patients With Advanced Malignancies NCT02404441 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) NCT00106145 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer o NCT00064636 | Millennium Pharmaceuticals, Inc. | Phase 1 |